Ultragenyx (RARE) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.90
- EPS estimate
- −$1.22
- EPS surprise
- +26.08%
- Revenue surprise
- +16.89%
- Revenue
- $214.0M
- Revenue estimate
- $183.1M
- Reported
- Aug 4, 2026
Ultragenyx reported Q2 2026 results on August 4, 2026, with a loss of $0.90 per share against an expected loss of $1.22, a 26.08% beat. Revenue was $214.0 million, well above the $183.1 million estimate. Compared with Q2 2025, the loss narrowed from $1.17 per share and revenue rose about 29% from $166.5 million.
Ultragenyx has reported a loss in all 20 quarters in the table, but losses have generally narrowed as revenue grew. Full-year losses were $10.11 per share in 2022, $8.33 in 2023, $6.34 in 2024 and $5.84 in 2025. Annual revenue rose from $363.2 million in 2022 to $672.7 million in 2025, up about 85%. Q2 2026 set the table's revenue high and its smallest quarterly loss. The first half of 2026 matched the first half of 2025 at a loss of $2.74 per share, on revenue about 15% higher. The company beat EPS estimates in only 7 of the 20 quarters.
Q3 results came out between November 2 and November 5 in each of the past five years, which points to early November 2026 for the next report. It will show whether revenue stays near the $214 million level of Q2.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$1.22 | −$0.90 | +26.08% | $214.0M | SEC |
| Q1 2026 | May 5, 2026 | −$1.50 | −$1.84 | −22.93% | $136.0M | SEC |
| Q4 2025 | Feb 12, 2026 | −$1.09 | −$1.29 | −18.07% | $207.0M | SEC |
| Q3 2025 | Nov 4, 2025 | −$1.23 | −$1.81 | −46.69% | $159.9M | SEC |
| Q2 2025 | Aug 5, 2025 | −$1.30 | −$1.17 | +9.81% | $166.5M | SEC |
| Q1 2025 | May 6, 2025 | −$1.60 | −$1.57 | +1.74% | $139.3M | SEC |
| Q4 2024 | Feb 13, 2025 | −$1.31 | −$1.39 | −6.23% | $164.9M | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.48 | −$1.40 | +5.65% | $139.5M | SEC |
| Q2 2024 | Aug 1, 2024 | −$1.66 | −$1.52 | +8.47% | $147.0M | SEC |
| Q1 2024 | May 2, 2024 | −$1.75 | −$2.03 | −16.19% | $108.8M | SEC |
| Q4 2023 | Feb 15, 2024 | −$1.71 | −$1.52 | +10.98% | $127.4M | SEC |
| Q3 2023 | Nov 2, 2023 | −$2.08 | −$2.23 | −7.35% | $98.1M | SEC |
| Q2 2023 | Aug 3, 2023 | −$2.09 | −$2.25 | −7.63% | $108.3M | SEC |
| Q1 2023 | May 4, 2023 | −$1.99 | −$2.33 | −16.95% | $100.5M | SEC |
| Q4 2022 | Feb 16, 2023 | −$2.14 | −$2.16 | −1.17% | $103.3M | SEC |
| Q3 2022 | Nov 2, 2022 | −$1.81 | −$3.50 | −93.26% | $90.7M | SEC |
| Q2 2022 | Jul 28, 2022 | −$1.75 | −$2.26 | −29.11% | $89.3M | SEC |
| Q1 2022 | May 5, 2022 | −$1.78 | −$2.19 | −22.96% | $79.9M | SEC |
| Q4 2021 | Feb 10, 2022 | −$1.37 | −$1.79 | −30.32% | $83.4M | SEC |
| Q3 2021 | Nov 2, 2021 | −$1.39 | −$1.08 | +22.50% | $81.6M | SEC |
Quarterly revenue
Frequently asked questions
When did Ultragenyx (RARE) last report earnings?
Ultragenyx last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did RARE beat earnings estimates?
Yes. Ultragenyx reported EPS of −$0.90 for Q2 2026 against a −$1.22 estimate — a 26.08% beat.
How much revenue did RARE report last quarter?
Ultragenyx reported $214.0M in revenue for Q2 2026, against a consensus estimate of $183.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.